不同eGFR分期下合并与不合并糖尿病、心血管疾病和心衰患者的医疗费用类型分析
本研究基于整合医疗系统的电子病历,纳入146132例有eGFR数据的患者,按eGFR分期及是否合并糖尿病、心血管疾病或心衰分组,分析1年随访期门诊、住院、急诊、药品、透析及总医疗费用。结果显示无合并症CKD患者总费用较无CKD者高31%(7374美元 vs 5631美元),住院费用占比随肾功能下降而升高,最高达66%。
要点
- 无合并症CKD患者总医疗费用比无CKD患者高31%。
- 住院费用占CKD无合并症患者总费用的35%,合并心衰者可达55%。
- 住院费用占比随肾功能下降而升高,最高达66%。
核心结论
- 肾功能越差且合并糖尿病、心血管疾病或心衰时,医疗总费用越高,住院费用占比也越大。
- 住院费用占比从CKD早期即开始增加,并随肾功能下降而加剧。
研究设计与样本
- 基于整合医疗系统电子病历的回顾性队列研究,纳入146132例2016或2017年有eGFR数据的患者。
- 按KDIGO定义的eGFR分期及是否合并糖尿病、心血管疾病或心衰分组,使用1年随访数据计算各类医疗费用。
主要发现
- 无合并症CKD患者平均总医疗费用为7374美元,无CKD者为5631美元,前者高31%。
- CKD无合并症患者住院费用占总费用35%,CKD合并心衰患者住院费用占比高达55%。
- 住院费用占比随肾功能下降而加速上升,最高达66%。
关键数值与推荐
- eGFR分期采用KDIGO定义的类别。
- 费用分析调整了年龄、性别和非白人种族。
临床怎么用
- 临床应关注CKD早期即出现的住院费用负担,尤其对合并糖尿病、心血管疾病或心衰的高危患者加强管理。
- 减少CKD发生、延缓进展和降低住院风险的治疗可能有助于减轻患者经济负担。
局限性
- 研究基于单一整合医疗系统电子病历,结果外推需谨慎。
- 为回顾性观察性研究,无法确定因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: CKD is associated with higher health care costs that increase with disease progression. However, research is lacking on the type of health care costs associated with CKD across all stages in a general population with a substantial comorbidity burden. METHODS: Using electronic medical records of an integrated delivery system, we evaluated health care costs by expenditure type in general and in patients with CKD by eGFR and presence of comorbidities. We categorized 146,132 patients with eGFR data in 2016 or 2017 and examined nonmutually exclusive groups according to presence of diabetes mellitus, cardiovascular disease, or heart failure. We used 1 year of follow-up data to calculate outpatient, inpatient, emergency, pharmaceutical, dialysis, and total health care costs by eGFR (Kidney Disease Improving Global Outcomes-defined eGFR categories), adjusted for age, sex, and nonwhite race. RESULTS: Mean total health care costs among patients with CKD without comorbidities were 31% higher than among patients without CKD ($7374 versus $5631, respectively). Hospitalizations accounted for 35% of total costs among those with CKD and no comorbidities but up to 55% among patients with CKD and heart failure. The proportion of costs attributable to hospitalizations accelerated with declining kidney function, reaching as high as 66%. CONCLUSIONS: Poorer kidney function and the presence of diabetes mellitus, cardiovascular disease, or heart failure drive substantial health care costs and increase the proportion of costs attributable to inpatient care. The large contribution of inpatient costs begins in earlier stages of CKD and escalates as kidney function declines. Additional therapies to reduce CKD incidence, slow CKD progression, and lower hospitalization risk are needed to benefit patients and reduce CKD's economic burden.
引用
- Nichols GA, Ustyugova A, Déruaz-Luyet A, et al. Health Care Costs by Type of Expenditure across eGFR Stages among Patients with and without Diabetes, Cardiovascular Disease, and Heart Failure. J Am Soc Nephrol. 2020. PMID: 32487562. doi:10.1681/ASN.2019121308
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。